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INTRODUCTION 
 
Long-lived individuals are central in studies of the 
determinants of a long and healthy life. Both genetic 
and environmental factors contribute to longevity, and 
research is increasingly more focused on the genetic 
part [1–4]. As highlighted in several Scandinavian twin 
studies, longevity clusters in families, which suggests 
the existence of genetic variants for survival [5–7]. 
These studies showed that lifespan is partly heritable, 
and that the heritability increases with age. One study 
indicated a genetic influence on human longevity, 
underscoring minimal genetic effects on lifespan for 
people under age 60 and then moderate genetic effects 
for people aged 60 and over [6]. However, few genetic 
or other pro-longevity factors have been identified, 
possibly due to “phenocopies” - those individuals that 
live long by chance. Some studies reported better health 
in long-lived siblings compared to sporadic long-livers, 
including a lower prevalence of Alzheimer’s disease 
and related disorders, diabetes, depression, heart failure 
and osteoporosis [8, 9]. One Dutch longitudinal study 
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Long-lived individuals are central in studies of healthy longevity. However, few pro-longevity factors have been 
identified, presumably because of “phenocopies”, i.e. individuals that live long by chance. Familial longevity 
cases may include less phenocopies than sporadic cases and provide better insights into longevity mechanisms. 
Here we examined whether long-lived female siblings have a better ability to avoid diseases at ages 65+ (proxy 
for “robustness”) and/or survive to extreme ages (proxy for “resilience”) compared to sporadic long-livers. A 
total of 1,156 long-lived female siblings were selected from three nationwide Danish studies and age-matched 
with sporadic long-lived female controls. Outcomes included cumulative incidence of common health disorders 
from age 65 and overall survival. Long-lived female siblings had lower risks of some but not all health 
conditions, most significantly, depression (OR=0.74; 95%CI=0.62-0.88), and less significantly hypertensive 
(OR=0.84; 95%CI=0.71-0.99) and cerebrovascular (OR=0.73; 95%CI=0.55-0.96) diseases. They also had 
consistently better survival to extreme ages (HR=0.71; 95%CI= 0.63-0.81) compared to sporadic long-livers. 
After adjustment for the diseases, the association with mortality changed only marginally suggesting central 
role of better physiological resilience in familial longevity. Due to their consistently better resilience, familial 
longevity cases could be more informative than sporadic cases for studying mechanisms of healthy longevity. 
 
www.aging-us.com 15158 AGING 
found better survival in long-lived siblings compared to 
sporadic long-livers [10]. However, these studies did 
not evaluate disease risk and survival in the same 
population and, therefore, were not able to examine the 
interplay between indicators of robustness and 
resilience, which is the focus of this study. 
 
Physical robustness could be defined as the ability to 
resist a deviation from the normal physical state and 
avoid an adverse health event [11]. In this framework, 
disease risk can be viewed as a proxy indicator of the 
whole-body robustness [12]. Physical resilience could 
be defined as the ability to bounce back, and quickly 
and completely recover after an adverse health event 
[11, 12].  The ability to survive to very old age could 
be used as a proxy indicator of the whole-body 
resilience [11, 12]. Physical resilience universally 
declines with age, increasing vulnerability to death as 
people grow older. Robustness also generally declines 
with age – manifested by increased risks of many 
health disorders (e.g. Alzheimer’s disease, stroke, 
renal and heart failure, fractures, pneumonia), and 
disabilities in the elderly; however, robustness may 
improve in some health domains, reflected in 
declining risks of certain chronic diseases (e.g. several 
cancers, diabetes, asthma) towards extreme ages [11–
13]. This indicates that the mechanisms underlying 
changes in physical robustness and resilience during 
aging are not necessarily (or entirely) the same. The 
same factor may have beneficial effects on resilience 
and adverse effects on robustness, and vice versa. For 
example, a chronically suppressed apoptosis in the 
body may contribute to both increased risk of cancer 
(lower robustness) in middle-old life and better 
survival at extreme ages (higher resilience) [14]. 
 
The long-lived individuals may live longer than the 
general population for various reasons. They may be 
more robust than the general population because they 
are able to avoid major diseases, or they may be more 
resilient because they are able to better survive after 
disease onset, or both. They may also live longer simply 
‘by chance’. This study investigates whether long-lived 
female siblings are more robust and/or resilient than 
sporadic (“non-familial”) long-lived women of the same 
age, and, specifically, whether they have a better ability 
to (i) avoid the common diseases of the elderly at ages 
65+ (proxy for robustness), and/or (ii) survive to 
extreme ages (proxy for resilience). We compared the 
cumulative incidence of the 20 most prevalent chronic 
conditions from age 65 between long-lived female 
siblings and sporadic long-lived Danish women. We 
also evaluated the difference in overall survival at the 
oldest-old ages between the familial and the sporadic 
long-livers, and examined factors contributing to this 
difference. Due to a scarce number of long-lived males, 
we used only data on long-lived females from three 






The study population was comprised of 2,312 long-
lived women: 1,156 female siblings and 1,156 controls. 
The median age on January 1st, 2006 was 91.3 years 
(range: 68.8-105.0), with a median age of 91.7 for 
siblings and 90.9 for sporadic long-lived women 
(p=0.013). These women were mainly widowed (79.4% 
in siblings and 76.7% in controls (Table 1)). Nearly two 
thirds of our population had a null Charlson 
Comorbidity Index (CCI) score, and the numbers were 
63.2% and 60.1% for siblings and controls (p=0.282), 
respectively. The prevalence of the 20 chronic 
conditions is shown in Table 1. The most prevalent 
condition was hypertensive disease (51.7% in siblings 
vs. 56.0% in controls, p=0.041) followed by respiratory 
allergy (42.8 vs. 43.4, p=0.769), cataract (39.1 vs. 39.5, 
p=0.831), hearing loss (38.4 vs. 33.4, p=0.013) and 
depression (32.1 vs. 38.9, p=0.001). If the Bonferroni 
correction or the false discovery rate (FDR) test [15] 
was used to account for multiple testing in Table 1, only 
the lower risk of depression among siblings remained 
statistically significant. 
 
The majority of the women reported medication 
prescription within the previous month - as median 
number of prescribed drugs (on average two; range: 0-
16). The proportion of siblings and controls receiving 
prescriptions was similar (72.8% and 74.4%, 
respectively, p=0.396); however, on average, siblings 
received a lower number of distinct drugs than controls 
(p=0.047). The prescribed drugs were mainly related to 
the nervous systems (39.7% in siblings vs. 43.8% in 
controls, p=0.047) and cardiovascular (37.2% vs. 




In the unadjusted models, long-lived siblings had a 
lower risk of hypertensive disease (OR=0.84, 
95%CI=0.71-0.99), chronic low respiratory diseases 
(CLRD) (OR=0.79, 95%CI=0.64-0.97), and depression 
(OR=0.74, 95%CI=0.62-0.88) than sporadic long-livers 
(Table 2). They also presented a tendency towards 
lower cumulative incidence of atrial fibrillation and 
flutter (OR=0.75 95%CI=0.54-1.04), cerebrovascular 
diseases (OR=0.80 95%CI=0.64-1.03) and dementia 
(OR=0.73 95%CI=0.51-1.04). On the other hand, 
siblings had a higher cumulative incidence of hearing 
loss (OR=1.24 95%CI=1.05-1.47) compared to the 
controls.
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Table 1. Characteristics of study population. 











  n (%) n (%) n (%) 
Marital status 
      
<0.001 
 
Unmarried 161 (7.0) 91 (7.9) 70 (6.1) 
 
 
Married 198 (8.6) 105 (9.1) 93 (8.0) 
 
 
Divorced 148 (6.4) 42 (3.6) 106 (9.2) 
 
 
Widowed 1,805 (78.0) 918 (79.4) 887 (76.7) 
 Charlson's comorbidity index 
      
0.282 
 
0 1,426 (61.7) 731 (63.2) 695 (60.1) 
 
 
1-2 759 (32.8) 362 (31.3) 397 (34.3) 
 
 
≥ 3 127 (5.5) 63 (5.5) 64 (5.6) 
 Specific comorbidities 
      
 
 
Disturbance in lipoprotein circulation and other lipids 115 (5.0) 54 (4.7) 61 (5.3) 0.503 
 
Diabetes 80 (3.5) 43 (3.7) 37 (3.2) 0.495 
 
Choroid and retina disorders 109 (4.7) 61 (4.6) 56 (4.8) 0.768 
 
Diseases of eye lens (cataracts) 909 (39.3) 452 (39.1) 457 (39.5) 0.831 
 
Glaucoma 298 (12.9) 152 (13.2) 146 (12.6) 0.710 
 
Hearing loss 831 (35.9) 444 (38.4) 387 (33.4) 0.013 
 
Hypertensive diseases 1,245 (53.9) 598 (51.7) 647 (56.0) 0.041 
 
Atrial fibrillation and flutter 163 (7.1) 71 (6.1) 92 (8.0) 0.088 
 
Ischemic heart diseases 304 (13.2) 159 (13.8) 145 (12.5) 0.389 
 
Cerebrovascular diseases 330 (14.3) 151 (13.1) 179 (15.5) 0.096 
 
Respiratory allergy 997 (43.1) 495 (42.8) 502 (43.4) 0.769 
 
Chronic low respiratory diseases 403 (17.4) 181 (15.7) 222 (19.2) 0.025 
 
Chronic Obstructive Pulmonary Disease 80 (3.5) 33 (2.9) 47 (4.1) 0.111 
 
Asthma 33 (1.4) 14 (1.2) 19 (1.6) 0.381 
 
Ulcers 156 (6.8) 78 (6.8) 78 (6.8) 1.000 
 
Osteoporosis 292 (12.6) 159 (13.8) 133 (11.5) 0.104 
 
Arthrosis 338 (14.6) 168 (14.5) 170 (14.7) 0.906 
 
Depression 821 (35.5) 371 (32.1) 450 (38.9) 0.001* 
 
Dementia 127 (5.5) 54 (4.7) 73 (6.3) 0.083 
 
Cancer 395 (17.1) 209 (18.1) 186 (16.1) 0.204 
Medication prescription 
      
0.396 
 
Yes 1,702 (73.6) 842 (72.8) 860 (74.4) 
 
 
No 610 (26.4) 314 (27.2) 296 (25.6) 
 Treated organs 
       
 
Alimentary tract and metabolism 668 (28.9) 325 (28.1) 343 (29.7) 0.409 
 
Blood and blood forming organs 468 (20.2) 230 (19.9) 238 (20.6) 0.679 
 
Cardiovacular system 882 (38.2) 430 (37.2) 452 (39.1) 0.346 
 
Dermatologicals 98 (4.2) 43 (3.7) 55 (4.8) 0.215 
 
Genito urinary system and sex hormones 106 (4.6) 49 (4.2) 57 (4.9) 0.426 
 
Systemic hormonal preparations 143 (6.2) 69 (6.0) 74 (6.4) 0.666 
 
Anti-infectives for systemic use 243 (10.5) 114 (9.9) 129 (11.2) 0.309 
 
Antineoplasic and immunomodulating agents 9 (0.4) 3 (0.3) 6 (0.6) 0.316 
 
Musculo-skeletal system 256 (11.1) 133 (11.5) 123 (10.6) 0.507 
 
Nervous system 965 (41.7) 459 (39.7) 506 (43.8) 0.047 
 
Antiparasidic, insecticides and repellents 45 (2.0) 18 (1.6) 27 (2.3) 0.175 
 
Respiratory system 174 (7.5) 82 (7.1) 92 (8.0) 0.430 
  Sensory organs 241 (10.4) 111 (9.6) 130 (11.3) 0.196 
a A p-value followed by an asterix (*) indicates a statistically significant finding after adjustment for multiple testing using the 
Bonferroni correction or FDR-test. 
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Table 2. Risk of presenting chronic conditions from age 65 and over among long-lived female siblings compared to 
sporadic long-lived Danish women, results from conditional logistic models, n=2,352. 
Chronic conditions 
Unadjusted models  Models adjusted for age 
OR  95% CI p-valuea  OR  95% CI p-valuea 
Cancer 1.15 (0.93-1.43) 0.202  1.27 (0.99-1.64) 0.059 
Hypertensive diseases 0.84 (0.71-0.99) 0.036  0.82 (0.68-0.99) 0.035 
Atrial fibrillation and flutter 0.75 (0.54-1.04) 0.082  0.79 (0.55-1.14) 0.213 
Ischemic heart diseases 1.11 (0.87-1.41) 0.860  1.03 (0.78-1.35) 0.862 
Cerebrovascular diseases 0.81 (0.64-1.03) 0.088  0.73 (0.55-0.96) 0.025 
Diabetes 1.20 (0.74-1.88) 0.480  1.46 (0.82-2.61) 0.199 
Disturbance in lipoprotein circulation and other lipids 0.88 (0.60-1.28) 0.495  0.92 (0.61-1.40) 0.711 
Depression 0.74 (0.62-0.88) 0.001*  0.72 (0.60-0.88) 0.001* 
Dementia 0.73 (0.51-1.04) 0.085  0.73 (0.48-1.13) 0.162 
Chronic low respiratory diseases 0.79 (0.64-0.97) 0.028  0.85 (0.67-1.07) 0.169 
Chronic Obstructive Pulmonary Disease 0.70 (0.44-1.09) 0.115  0.68 (0.42-1.12) 0.128 
Asthma 0.74 (0.37-1.45) 0.386  0.85 (0.39-1.85) 0.681 
Respiratory allergy 0.98 (0.83-1.15) 0.773  1.11 (0.92-1.33) 0.269 
Choroid and retina disorders 0.94 (0.65-1.38) 0.772  0.94 (0.60-1.45) 0.764 
Diseases of eye lens (cataracts) 1.02 (0.86-1.20) 0.831  0.92 (0.76-1.11) 0.381 
Glaucoma 1.05 (0.82-1.34) 0.709  1.08 (0.81-1.44) 0.598 
Hearing loss 1.24 (1.05-1.47) 0.013  1.14 (0.94-1.39) 0.189 
Ulcers 1.00 (0.72-1.38) 1.000  0.90 (0.62-1.31) 0.581 
Osteoporosis 1.23 (0.96-1.58) 0.102  1.28 (0.96-1.69) 0.090 
Arthrosis 0.99 (0.78-1.24) 0.907  0.84 (0.64-1.10) 0.201 
a A p-value followed by an asterix (*) indicates a statistically significant finding after adjustment for multiple testing using the 
Bonferroni correction or FDR-test. 
 
After adjustment for age, the long-lived female siblings 
still had a significantly lower risk of hypertensive disease 
(OR=0.82 95%CI=0.68-0.99) and depression (OR=0.72 
95%CI=0.60-0.88) compared to the sporadic long-livers. 
They also had a significantly lower risk of 
cerebrovascular diseases (OR=0.73 95%CI=0.55-0.96). 
The risk of hearing loss did not remain significant after 
adjustment for age. However, the risk of  cancer became 
higher (OR=1.27 95%CI=0.99-1.64) in long-lived female 
siblings compared to the sporadic long-livers after 
adjustment for age, though with marginal significance. If 
the Bonferroni correction or the FDR test was used to 
account for multiple testing, only the association with 




At the end of the follow-up, 1,763 (76.3%) women,  
833 (72.1%) siblings, and 930 (80.4%) controls were 
deceased. Overall survival for siblings and controls  
was 89% and 83% at 1 year, 66% and 56% at 3 years,  
and 47% and 36% at 5 years (p<0.001), respectively 
(Figure 1).  
 
Long-lived female siblings had better 5-year overall 
survival than sporadic long-lived women (hazard ratio 
(HR)=0.71 95%CI=0.63-0.81) (Table 3). After 
adjustment for age, the HR of death among siblings 
compared to controls was lower (HR=0.68 
95%CI=0.58-0.79), while it increased after adjustment 
for marital status (HR=0.72 95%CI=0.63-0.82), 
cerebrovascular diseases (HR=0.72 95%CI=0.63-0.82), 
depression (HR=0.73 95%CI=0.64-0.83), number of 
prescribed drugs (HR=0.72 95%CI=0.63-0.82) or 
nervous system drugs prescriptions (HR=0.72 
95%CI=0.63-0.82), and it remained unchanged after 
adjustment for hypertensive diseases (HR=0.71 
95%CI=0.63-0.81). In other words, the risk of death did 
not change or change only marginally after the 
adjustment, and remained significant for all covariates. 
Thus, after adjustment for all the variables 
simultaneously, female siblings still had significantly 





People may live long for various reasons including 
better robustness or better resilience, or both. They may 
also live longer lives simply by chance. In this study, 
we examined whether the long-lived female siblings are 
more robust and/or more resilient than sporadic long-
lived women. Our results indicate that the long-lived 
siblings may be more robust to some health conditions 
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(hypertension, cerebrovascular disease, depression), and 
less robust to some other (cancer); though only the risk 
of depression (OR=0.72; p-value=0.001) remained 
statistically significant after adjustment for multiple 
testing [15]. Our results strongly support the possibility 
that the long-lived female siblings are more resilient 
than sporadic long-livers because they show 
significantly better survival at extreme ages, even after 
controlling for all covariates/comorbidities. This 
indicates that familial longevity could be mainly related 
to a better resilience as the ability to overcome various 
life and health problems, rather than to a simply good 
health, and that being not depressed may be a key factor 
supporting organism’s robustness in advanced years  
of life.   
 
Findings from earlier US studies that used samples of 
LLFS data suggest that long-lived siblings could be 
more robust to some diseases. Ash et al. [8] found lower 
risks of depression, Alzheimer’s disease, diabetes, heart 
failure, and some other conditions, in the long-lived 
LLFS siblings compared to the sporadic long-lived 
Medicare beneficiaries [8]. Unlike  Ash et al., we found 
no evidence for a significantly different risk of dementia 
between the long-lived female siblings and controls [8]. 
However, Ash et al. studied a combination of both 
sexes, whereas our study focused only on females, 
which might lead to the difference in results.  Similar to 
our findings, Newman et al. reported a lower risk of 
hypertension in LLFS compared to the Framingham 
Heart Study (FHS), but not to the Cardiovascular Health 
Study (CHS) and the New England Centenarian Study 
(NECS) participants [9]. That study also reported mixed 
results regarding stroke, with a higher risk in long-lived 
LLFS siblings compared to CHS and FHS, and no 
significant difference for NECS participants [9], while 
our results indicated a lower risk of cerebrovascular 
disease in the long-lived female siblings in the age-
adjusted analysis.   
 
In our study, we found a marginally significant higher 
risk of cancer among the long-lived female siblings 
compared to sporadic long-livers. Ukraintseva et al. 
earlier suggested potential biological mechanisms of 
trade-offs between extreme longevity and cancer risk, 
including antagonistic pleiotropic role of some genetic 
and non-genetic factors in aging and cancer 
development, which could be applicable to these results 
[14]. Other studies did not report a significant 
difference in the risk of cancer between long-lived 
LLFS siblings and controls [8, 9], but this may be due 
to differences in research design. A higher risk of 
hearing loss in the long-lived female siblings compared 
to sporadic long-livers did not remain significant after 
adjustment for age. So, we may assume that this 
difference was related to the age difference between 
siblings and controls. If multiple testing was considered 
using the conservative Bonferroni correction or the 
FDR test, only the lower risk of depression among 
siblings remained statistically significant [15].  
 
Regarding survival to extreme ages, we observed a 
better overall survival of female long-lived siblings 
compared to sporadic long-livers. Similar findings were 
reported in a Dutch study that also showed better 
survival of the long-lived siblings at high ages, as 
compared to long-lived sporadic controls [10]. The 
association remained statistically significant after 





Figure 1. 5-year survival of siblings and controls from January 1st, 2006, Kaplan-Meier curve. 
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Table 3. Risk of death in high age among long-lived female siblings compared to sporadic long-lived Danish women, 
results from stratified Cox models, n=2,352. 
Models HR  95% CI p-value 
Without covariate 0.71 [0.63-0.81] <0.001 
Including age 0.68 [0.58-0.79] <0.001 
Including marital status 0.72 [0.63-0.82] <0.001 
Including hypertensive diseases 0.71 [0.63-0.81] <0.001 
Including cerebrovascular diseases 0.72 [0.63-0.82] <0.001 
Including depression 0.73 [0.64-0.83] <0.001 
Including no. of prescribed drugs 0.72 [0.63-0.82] <0.001 
Including nervous system drugs prescription 0.72 [0.63-0.82] <0.001 
Including age, marital status 0.69 [0.60-0.81] <0.001 
Including hypertensive diseases, cerebrovascular diseases, depression 0.73 [0.64-0.83] <0.001 
Including age, marital status, all the previous chronic conditions 0.72 [0.62-0.84] <0.001 
Including age, marital status, all the previous chronic conditions, no. of 
prescribed drugs 
0.72 [0.62-0.85] <0.001 
 
It should be emphasized that none of the above studies 
considered indicators of physiological robustness and 
resilience in the same population, whereas in our large 
population-based study, we investigated both disease 
risks and survival to extreme ages in the same 
individuals. Our results suggest that better physiological 
robustness (manifested by lower disease risks) does not 
entirely explain better resilience (manifested by a higher 
survival to extreme ages) of female members of the 
long-lived families, as compared to sporadic long-livers. 
And adjustment for the above diseases, to which the 
long-lived female siblings were more robust, did not 
change the association, or did so only marginally.  
 
We showed that longevity clustered in families can lead 
to a significantly lower mortality risk at extreme ages 
compared to sporadic long-livers. This suggests that 
resilience has similar biological mechanisms in the 
long-lived siblings influenced by common genetic and 
other familial factors. Indeed, in the first part of their 
lives, siblings share many environmental factors (e.g., 
socioeconomic status, place of residence, lifestyle). In 
addition, studies have highlighted the influence of 
genetic effects on lifespan at older ages, indicating that 
genetic factors could play a major role in the familial 
longevity [6]. Genetic factors are more likely than other 
factors to be related to resilience in long-lived siblings 
compared to sporadic long-livers, although other factors 
should also be explored. 
 
There are some limitations to this study. First, long-lived 
female siblings were, on average, slightly but significantly 
older than the sporadic long-lived women even after 
matching on age. However, our analyses were adjusted 
for age. This adjustment did not lead to different results in 
the survival analyses. In fact, the adjustment for age only 
changed the HR slightly, and the association became 
stronger. Second, the condition or disease for which the 
medication was prescribed (indication code) was not 
available [16]. Not considering the indication codes could 
lead to a potential information bias with an overestimation 
of some chronic conditions. Nonetheless, if there was 
information bias, it was non-differential with an 
overestimation in long-lived siblings and controls. Third, 
only chronic conditions diagnosed through medication or 
in hospitals were considered. Consequently, some 
conditions could not be included. However, we focused 
on the 20 most prevalent chronic conditions in Danes 
aged 75 and over [17] and defined them based on 
validated definitions [16]. Finally, the initial study, which 
in 2004 identified the long-lived families that were 
included in the present study, did not use current 
definitions of longevity such as top sex and birth cohort 
survival percentiles [18, 19]. In our study population, 
99.5% of the recruited families included at least two 
siblings who survived to age 90 years, whereas for the 
remaining families, one sibling survived well past 90 
years and at least one other sibling survived to age 89 
years. With our definition of longevity, a large sibship – 
everything else equal – has a higher probability of 
becoming a long-lived family compared to a sibship of 
say two. Recognizing this bias, we have been collecting 
evidence to address the potential size of the bias. We 
found that the long-lived siblings in our study were from 
sibships with an average of 7.2 siblings compared to 6.6 
in 358 control families that were selected among families 
with at least two children. A difference this size seems 
unlikely to be of importance for late life disease and 
survival. Moreover, we cannot exclude that some controls 
were from non-identified long-lived families, but they 
would be rare. Also, males have higher mortality 
throughout life compared to females.  Therefore, a study 
of similar long-lived men would have been an even more 
selected study sample and bring additional information to 
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our findings. However, in our study we were not able to 
identify a sufficient number of male controls in the 5% 
sample of the Danish population to allow meaningful 
analyses. 
 
The main strength of this work lies in the study design 
consisting of long-lived female siblings matched on age 
with female controls from a representative sample of the 
Danish population. Thus, the registry-based study 
design permitted avoidance of selection bias. Long-
lived siblings and controls were all identified in high-
quality National Danish registers, also leading to a large 
sample size. Finally, the definition of chronic conditions 
was based on both hospital and medication data [16]. In 
this way, we identified individuals with different 
disease levels, although not all individuals. 
 
In conclusion, long-lived female siblings demonstrated 
better robustness to some health conditions (especially, 
depression), while increased vulnerability to some other 
diseases (cancer). Physiological resilience (manifested in 
higher chances of survival to extreme ages) was 
consistently better in the long-lived female siblings than in 
their age-peers from general population. This indicates that 
the ability to overcome deleterious life events may be more 
important for extreme longevity than a good health alone, 
and that avoiding depression is major factor of maintaining 
physical robustness in familial longevity. A consistently 
better survival of the long-lived siblings also suggests that 
resilience may have stronger genetic component in familial 
longevity, warranting further investigation. Overall, results 
of this study indicate that long-lived siblings are excellent 
candidates for healthy longevity studies, and that familial 
longevity cases could be more informative than sporadic 
cases for studying mechanisms of longevity. Since health 
phenotypes such as discharge diagnoses of chronic 
conditions and medication could not explain better 
resilience of the long-lived female siblings, a next step can 
be to focus on other factors that might explain their better 
resilience,  such as response to acute health events, 
dynamic changes in functional status, cognitive 
functioning, or psychological factors [11; 20–22]. 
Cognitive and physical functioning are known to be highly 
predictive of survival in the very old individuals [20].  In 
addition, it would be reasonable to explore last year of life 
events, or the cause of death in long-lived siblings 
compared to sporadic long-livers to examine whether they 
experience different life events compared to sporadic long-
lived women.  
 




The identification of long-lived siblings was undertaken 
in three nationwide, consecutive studies in Denmark, 
for which recruitment ran sequentially during the years 
2004 to 2009: the Danish Oldest Siblings (DOS) pilot 
study, the Genetics of Healthy Ageing (GeHA) study 
[23], and the Danish part of the Long Life Family Study 
(LLFS) [24]. All individuals born before April 2, 1918, 
and alive in 2004 were identified in the Danish Civil 
Registration System (CRS). Long-lived siblings were 
defined in different ways depending on the study. 
Recruitment to DOS was conditional on both siblings 
being alive and 88 years or older; recruitment to GeHA 
required both siblings to be alive and above age 90, and 
the LLFS recruited only families with a family 
longevity index (FLoSS) score above 7 [24]. In all, 
3,972 siblings from 659 families were enrolled in either 
DOS, GeHA, or LLFS, with 659 siblings from 114 
families in DOS, 2,736 siblings from 469 families in 
GeHA, and 577 siblings from 76 families in LLFS. 
 
Long-lived female siblings enrolled in these studies and 
alive on January 1st, 2006 were included. Each female 
sibling was matched with one female control from the 
Danish population alive on January 1st, 2006 and 
randomly selected on age (+/- 2 years). 
 
Danish national population-based registers  
 
The information used in this study was mainly extracted 
from the Danish national population-based registers 
presented below. 
 
The Danish civil registration system (CRS) 
The CRS, which covers the entire population alive and 
residing in Denmark since April 2, 1968, contains 
information on each resident’s vital status, sex, place 
and date of birth as well as familial links (e.g. parents, 
siblings, spouse) [25, 26]. All persons registered in 
CRS are assigned a unique personal identification 
number which is used in all national registers, enabling 
accurate linkage between all national registers. Once a 
person has been assigned a unique personal 
identification number, the same number will not be 




The Danish National Patient Register (NPR) is a health 
register established in 1977 [27, 28]. The NPR covers 
inpatients and somatic wards as well as outpatients and 
psychiatric wards since 1995. The reported data are 
administrative (e.g. patient’s municipality, identification 
of hospital ward, date and time of activity, and 
information on accidents leading to hospital contact) 
and clinical (e.g. diagnoses and surgical procedures). 
Different types of diagnoses are recorded: primary 
diagnoses (main reason for hospitalization), secondary 
diagnoses (supplementing the primary diagnosis), 
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referral diagnoses (reason for referral), temporary 
diagnoses and complications. 
 
The Danish Cancer Registry (DCR) contains records of 
all incidences of malignant neoplasms in the Danish 
population from 1943 onwards [29]. The register is 
considered almost complete and has a high degree of 
validity [29, 30]. 
 
The Danish National Prescription Registry (DNPR) 
provides individual-level information on dispensed 
prescriptions for each person resident in Denmark since 
1995 [31, 32]. DNPR contains information on all 
prescription drugs dispensed at Danish community 
pharmacies as well as prescriptions dispensed to 
residents of long-term care institutions (e.g. nursing 
homes). The register records information related to drug 





The first outcome was the cumulative incidence from 
age 65 of the 20 most prevalent chronic conditions in 
Danes aged 75 and older [17]: cancers, hypertensive 
disease, atrial fibrillation and flutter, ischemic heart 
disease (including myocardial infarction), 
cerebrovascular diseases (including stroke), diabetes, 
disturbance in lipoprotein circulation and other lipids, 
depression, dementia, chronic low respiratory diseases 
(CLRD), chronic obstructive respiratory disease 
(COPD), asthma, respiratory allergy, choroid and 
retina disorders, diseases of eye lens (cataract), 
glaucoma, hearing loss, ulcers, osteoporosis, arthrosis. 
Except for cancers, all diseases were identified through 
the NPR and/or the DNPR using the register-based 
definitions defined by Hvidberg et al [16] 
(Supplementary Table 1). Cancers were identified using 
the DCR. 
 
The second outcome was overall survival. Survival time 
was calculated from January 1st, 2006 to the date of 
death, emigration or to the date of last follow-up (July 
1st, 2013), whichever came first. All-cause mortality 
was defined as death from any cause. Patients still alive 




Analyses were adjusted for the following factors, 
usually associated with overall survival in older adults: 
marital status, Charlson’s comorbidity index (CCI [33]), 
medication prescription and organs treated by 
prescription drugs. Marital status was considered on 
January 1st, 2006 from the CRS. The CCI was 
constructed from hospital data in the 10 years prior to 
January 1st, 2006. It was based on primary and 
secondary disease diagnoses recorded in the NPR. In 
order to capture medical habits and general health in 
addition to CCI, medication prescription (yes versus 
no), the number of prescribed drugs and treated organs 
within the month prior to January 1st, 2006 were 
considered. The treated organs referred to level 1 
Atomic Therapeutic Chemical groups concerned by 
medication prescription. Prescribed drugs were assessed 
to evaluate polypharmacy and as a proxy for general 




The cumulative incidence between female siblings and 
controls was compared by performing conditional 
logistic regression models based on matching data. 
 
Survival time from January 1st, 2006 was described with 
Kaplan-Meier curves for female siblings and controls 
separately and compared using the logrank test. 
Survival analyses were performed using stratified Cox 
proportional hazards models based on the matching data 
with and without potential confounding covariates. 
Proportional-hazards assumption was tested using 
Schoenfeld residuals. 
 
The study has been approved by The Regional 
Scientific Ethical Committees for Southern Denmark 
(S-VF-20030227) and The Danish Data Protection 
Agency (# J.nr. 2008-41-1753). 
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Supplementary Table 1. Coding of the 20 most prevalent conditions in Danes aged 75+ on National Danish 
databases. 
No. Conditions Databases* Definition 
1 Malignant neoplasms DNC All except ICD-10 C44 
 Endocrine nutritional and metabolic diseases   
NPR ICD-8: 279 
ICD10: E78 
DNPR ATC: C10 
NPR ICD-8: 249, 250 
ICD-10: E10-E14 
DNPR ATC: A10A, A10B. 
At least two prescriptions. 
 Diseases of the eye and adnexa and diseases of the ear and mastoid process 
4  Choroid and retina disorders NPR ICD-8: 367, 376, 377.0-377.4 
ICD-10: H31, H32, H34, H35 
5  Diseases of eye lens (cataracts) NPR ICD-8: 374 
ICD-10: H25-H28 
NPR ICD-8: 375 
ICD-10: H40-H42 
DNPR ATC: S01E 
7  Hearing loss NPR ICD-8: 389, 781.3 
ICD-10: H90, H910, H912, H913, 
H918, H930, H932, H933, H911, H919 
 Diseases of the circulatory system   
NPR ICD-8: 400-404 
ICD-10: I10-I15 
DNPR Combination treatment with at least 
two of the following classes of 
hypertensive drugs with ATC codes: 
- α Adrenergic blockers (C02A, C02B, 
C02C) 
- Non-loop diuretics (C02DA, C02L, 
C03A, C03B, C03D, C03E, C03X, 
C07C, C07D, C08G, C09BA, C09DA, 
C09XA52) 
- Vasodilators (C02DB, C02DD, 
C02DG, C04, C05) 
- β Blockers (C07) 
- Calcium channel blockers (C07F, 
C08, C09BB, C09DB) 
- Renin-angiotensin system inhibitors 
(C09) 
9  Atrial fibrillation and flutter NPR ICD-8: 427.93, 427.94 
ICD-10: I48 
10  Ischaemic heart diseases (including myocardial infarction) NPR ICD-8: 410-414 
ICD-10: I20-I25 
11  Cerebrovascular diseases (including stroke) NPR ICD-8: 430-438 
ICD-10: I60-69, G45, G46 
DZ501 A-diagnosis in combination 
with I61, I63-64 as A- or B- diagnosis 
 Diseases of respiratory system   
NPR ICD-8: 507.00-507.03, 507.08, 507.09 
ICD-10: J30 except J30.0 
DNPR ATC: V01AA02, V01AA03, 
V01AA05, V01AA11, R01AC, 
R01AD, R06A, S01G, R01BA52 
NPR ICD-8: 490-492 
ICD-10: J40-43, J47 
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DNPR ATC: R03AC, R03AK, R03BA, 
R03BB, R03CC, R03DA, R03DC, 
V03AN01 
Except if cystic fibrosis (ICD-8 273.0, 
ICD-10 E84) or COPD medication or 
asthma specific medication 
NPR ICD-8: 491, 492 
ICD-10: J44 
DNPR ATC: R03AC18, R03AC19, R03AL02, 
R03AL03, R03AL04, R03BB04, 
R03BB05, R03BB06, R03DX07 
Except if cystic fibrosis (ICD-8 273.0, 
ICD-10 E84) 
NPR ICD-8: 493 
ICD-10: J45-J46 
DNPR ATC: R03DC03 
Except if cystic fibrosis (ICD-8 273.0, 
ICD-10 E84) 
 Diseases of digestive system   
NPR ICD-8: 531-534 
ICD-10: K25-K27 
DNPR ATC: A02BD 
 Diseases of the musculoskeletal system and connective tissue   
NPR ICD-8: 723.0 
ICD-10: M80-M81 
DNPR ATC: M05BA01, M05BA04, 
M05BA06, M05BA07, M05BB01, 
M05BB03, G03XC01, H05AA02, 
H05AA03 
18  Arthrosis NPR ICD-10: M15-M19 
 Mental and behavioural disorders   
NPR ICD-8: 296.09, 296.29, 296.99, 298.09, 
300.49, 300.19 
ICD-10: F32, F33, F34.1, F06.32 
DNPR ATC: N06A  
NPR ICD-8: 290.09, 290.10, 290.11, 290.12, 
290.13, 290.14, 290.15, 290.16, 290.17, 
290.18, 290.19, 293.09 
ICD-10: F00, G30, F01, F02.0, F03.9, 
G31.8B, G31.8E, G31.9, G31.0B 
DNPR ATC: N06D 
* DNC: Danish Cancer Registry, NPR: Danish National Patient Register, DNPR: Danish National Prescription Register. 
 
